• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Product Mix of Novartis
 

Product Mix of Novartis

on

  • 1,598 views

 

Statistics

Views

Total Views
1,598
Views on SlideShare
1,598
Embed Views
0

Actions

Likes
1
Downloads
54
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Product Mix of Novartis Product Mix of Novartis Presentation Transcript

    • Presented By,Group No-01Animesh Amal (01)Madhura Jagtap (10)Bosco James (15)Shafaatali (18)Bhavika Sachdev (23)
    • Contents• Mission & Vision• Novartis India• History• People• Top 10 Brands• Current Alliance• Product Mix• Presence• Financial Data• Stock Price• R & D• References
    • Mission & Vision• We want to discover, develop and successfullymarket innovative products to prevent andcure diseases, to ease suffering and toenhance the quality of life.• We also want to provide a shareholder returnthat reflects outstanding performance and toadequately reward those who invest ideas andwork in our company.
    • Novartis IndiaMissionInnovative products, Outstanding performance,Ideas and work.VisionA better today and tomorrow for patients.DirectorsChristopher Snook (Chairman)Ranjit Shahani (Vice Chairman & M.D.)
    • History1996 – The shareholders of Sandoz and Ciba-Geigy approve of the merger.1997- Novartis announces to acquire cropprotection business of Merck & co.2000 - Novartis seeds are merged withAstrazeneca’s agribusiness operations to formSyngenta.2001- FDI grants approval of Glivec.2003- Novartis unites it’s generics business underone single global brand - Sandoz.
    • History of Novartis195819701996Present
    • PeopleFull-time associates 2012 total: 127 724Associates by region, 2012
    • Top 10 Brands of Novartis India
    • Current Alliance of Novartis
    • Product MixProduct Mix WidthPharmaceuticalsAlcon (Eye Care)Sandoz(Generics)Over The CounterVaccines and DiagnosticsAnimal Health
    • PharmaceuticalsAutoinflammatory and AutoimmuneDiseaseIlarisHypertension Amturnide, Diovan, Exforge, LotrelMetabolism Cubicin, Tyzeka / SebivoNeuroscience Clozaril, Comtan, Extavia, FanaptOncology Exjade, Femara, Tasigna, GleevecOphthalmology LucentisRespiratory Foradil, Xolair, TOBI, Arcapta NeohalerTransplantation Myfortic, Simulect, Neoral, ZortressVirology/ Anti – invectives Cubicin, Tyzeka / SebivoOther Lamisil, Famvir, Riamet, Voltaren, Reclast
    • Alcon (Eye Care)Surgical Infiniti , Constellation,intraocular lenses ,Ophthalmic Pharmaceuticals Travatan, Moxeza, Pataday,NevanacVision Care Air Optix brand of breathablecontactlenses, Dailies, FreshLookcolored lenses
    • Sandoz(Generics)Anti-coagulant Lovenox®Anti-infective Augmentin®Respiratory system Fluimucil®Hypertension Lotrelc®Analgesic Duragesic®Proton pump inhibitor Prevacid®Ulcer & heartburn treatment Prilosec®Cholesterol lowering treatment Zocor®Transplantation Prograf®
    • OTCNasal decongestant OtrivinPaediatric nasal decongestant ProRhinelCough suppressant SinecodAntihistamine Tavegyl/TavistCough and cold treatment TherafluPaediatric cough and cold treatment TriaminicCough/ Cold/ Respiratory
    • Contd……Fiber supplement BenefiberLaxative Ex-LaxGas reliever Gas-XAntacid MaaloxFrequent heartburn treatment Prevacid24HRDigestive Health
    • Contd……Pain reliever ExcedrinAnti-inflammatory VoltarenCalcium supplement CalSourceSkin irritation treatment FenistilAntifungal treatment LamisilSmoking cessation treatment Nicotinell/Thrive/HabitrolSystemic antivaricose treatment VenorutonPain and Others
    • Vaccines and DiagnosticsSeasonal flu (influenza) Agrippal, Begrivac, Optaflu, Fluad, FluvirinH1N1 Focetriameningococcal disease Menveomeningitis Menjugatestimulating the bodys immuneresponseIXIAROTickborne encephalitis Encepur NRabies prevention RabAvertDiphtheria Quinvaxempoliovirus type 1, 2 and 3 Polioral
    • Animal HealthPet Health Atopica, Capstar, Deramaxx , Fortekor,Interceptor, Milbemax, Milbemax, Prac-tic,SentinelLivestock Acatak Duostar, CLiK, Denagard, Fasinex,Vira Shield , ZOLVIXBioprotection Agita 10WG, Larvadex, Neporex, Oxyfly,Ratsnip, Spy, Virusnip
    • PresenceNorwayPhilippinesPolandPortugalRussiaSlovakiaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUSAVenezuelaFinlandFranceGermanyGreeceHong KongHungaryIndiaIndonesiaItalyJapanKoreaMexicoArgentinaAustraliaAustriaBangladeshBelgiumBrazilCanadaChileChinaColombiaDenmarkEgyptNorway
    • PharmaceuticalsAlcon Sandoz Vaccines andDiagnosticsConsumerHealthUnited States 32% 10 392 39% 4 016 32% 2 786 40% 746 17% 652Europe 32% 10 238 27% 2 710 49% 4 225 35% 658 50% 1 877Asia/Africa/Australasia26% 8 434 23% 2 395 12% 1 057 15% 273 21% 777Canada andLatin America10% 3 089 11% 1 104 7% 634 10% 181 12% 429Total 32 153 10 225 8 702 1 858 3 735EstablishedMarkets77% 24 778 76% 7 805 74% 6 402 77% 1 434 65% 2 415EmergingGrowthMarkets23% 7 375 24% 2 420 26% 2 300 23% 424 35% 1 320Total 32 153 10 225 8 702 1 858 3 7352012 NET SALES BY REGION AND SEGMENT
    • 2012 NET SALES BY SEGMENT% USD in millionsPharmaceuticals 57 32 153Alcon 18 10 225Sandoz 15 8 702Vaccines and Diagnostics 3 1858Consumer Health 7 3735Total 56 673
    • Pharmaceuticals :- Sales : Rs. 330.5 Cr. (Half year ended September 2012) Growth : 11.8%OTC :-Sales : Rs. 48.2 cr. (Half year ended September 2012)Growth : - 10.07%Animal Health :-Sales : Rs. 47.6 Cr. (Half year ended September 2012)Growth : 16.95%Sandoz(Generics):-Sales : Rs. 30.6 Cr. (Half year ended September 2012)Growth : 5.15%Net sales (India)
    • Stock Price of NovartisBSE:500672BSE 590.00 4.05 (+0.69%)VOLUME 42,989PREV. CLOSE 585.95OPEN PRICE 587.95BID PRICE (QTY.) 590.00 (1,510)OFFER PRICE (QTY.) 0.00 (0)YESTERDAYS LOW/HIGH 583.10 594.0052 WK LOW/HIGH 574.00 934.20(as per 14/3/13 data)
    • ROLE OF R&D• Targeting rare and neglected diseases• Ethical research• Responsible R&D
    • R&D LOCATIONS OF NOVARTIS• NIBR PHARMA DEVELOPMENT-EMERYVILLE US -INDIA-LA JOLLA CALIFORNIA US -CHINA- FORT WORTH TX USA -JAPAN-CAMBRIDGE US-EAST HANOVER US-HORSHAM UK VACCINES AND DIAGNOSTIC-BASEL SWITZERLAND -US-SIENA ITALY -ITALY-SINGAPORE-SHANGHAI CHINA
    • References• Balance Sheet (2012) of Novartis• http://www.fiercebiotech.com/story/novartis-lists-its-top-blockbuster-prospects-11-15/2011-07-19• http://management.fortune.cnn.com/tag/blockbuster-drugs/• http://www.novartis.com/• http://www.novartis.com/products/pharmaceuticals-therapeutic-area.shtml• http://www.novartis.com/products/index.shtml